New drug shows promise for Hard-to-Treat cancers
NCT ID NCT04118114
First seen May 06, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or other types) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if patients were benefiting. The goal was to see if the drug could shrink tumors or stop them from growing, and to understand its side effects and which patients might respond best.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Center Singapore
Singapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.